RxDoctor Payments DataLook up a doctor →

James Smith, MD

Interventional Cardiology · Shreveport, LANPI 1881684256

Payments from drug & device makers

$45,205in general payments, 2019–2025

Across 364 payments — averaging $124.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$22K
  • Sanofi-aventis U.S. LLC$8K
  • AstraZeneca$4K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Silk Road Medical, Inc.$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$897
  • plus $5K from 34 others

What the payments were for

  • Consulting fees$8,00026%
  • Speaking & faculty fees$9,22030%
  • Travel & lodging$3,44011%
  • Food & beverage$9,93132%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,205 in reported general payments places this provider in the 75th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$503,172
Medicare patients
1,591
Services billed
6,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban822$690,968
EntrestoSacubitril/Valsartan322$279,456
XareltoRivaroxaban186$164,247
Repatha SureclickEvolocumab151$102,833
MultaqDronedarone Hcl109$97,414
FarxigaDapagliflozin Propanediol77$57,717
JardianceEmpagliflozin80$51,652
Praluent PenAlirocumab18$11,710
Metoprolol Succinate899$10,648
NexlizetBempedoic Acid/Ezetimibe26$10,353
Rosuvastatin Calcium893$10,206
VascepaIcosapent Ethyl20$8,250
Ezetimibe400$7,870
Propafenone Hcl191$6,635
Dofetilide23$6,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$142$690,968822 claims
NovartisEntresto$172$279,456322 claims
Johnson & JohnsonXarelto$111$164,247186 claims
Sanofi-aventis U.S. LLCMultaq$8,298$97,414109 claims
AstraZenecaFarxiga$4,486$57,71777 claims
Boehringer IngelheimJardiance$294$51,65280 claims
Esperion Therapeutics, Inc.Nexlizet$221$10,35326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →